5 million for a personal cancer diagnosis

Russian cancer diagnostics service Solo attracted 5 million rubles

Oleg Ovechkin, Rusbase

The venture fund Primer Capital has invested 5 million rubles in the biomedical company CSB Genomics, part of the Atlas holding and engaged in a service for the selection of personalized anti-tumor therapy Solo, the fund told Rusbase.

It is reported that the Solo service uses the latest cancer diagnostic techniques like NGS sequencing for the comprehensive study of oncological diseases.

Detailed diagnostic results are published in the electronic office of the attending physician, which helps him to prescribe personalized, that is, the most effective treatment for a particular patient. Primer Capital notes that this allows you to reduce the costs and time for treatment.

It is reported that the service will be available to Russian patients "soon", and Solo took more than a year to develop. The prices for the services of the service are not disclosed.

At the end of 2015, Atlas stated that Solo has no competitors in Russia. In the United States, Foundation Medicine is engaged in a service with similar functionality (it went IPO in 2013, at the moment the company's market capitalization is estimated at $775.7 million).

The startup "CSB Genomics" is a resident of the biomedical cluster "Skolkovo". Atlas acquired a majority stake in the company in October 2015. In its research, the project cooperates with MIPT, the Institute of Chemical Biology and Fundamental Medicine of the SB RAS and other organizations.

Portal "Eternal youth" http://vechnayamolodost.ru  30.09.2016